Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (2322)	3/3/2005 3:59:54 PM
From: tuck	Read Replies (1) \| Respond to of 3044

[Bortezomib-Induced Severe Hepatitis in Multiple Myeloma: A Case Report] >>Arch Intern Med. 2005 Feb 28;165(4):464-465. Bortezomib-Induced Severe Hepatitis in Multiple Myeloma: A Case Report. Rosinol L, Montoto S, Cibeira MT, Blade J. Hematology Department, Institut d'Investigacions Biomediques August Pi I Sunyer, Hospital Clinic, Barcelona, Spain. Bortezomib is a novel proteasome inhibitor with significant antimyeloma activity. Its toxicity is manageable, and the most frequent adverse effects mainly consist of gastrointestinal symptoms, peripheral neuropathy, neuropatic pain, and thrombocytopenia. Severe liver toxicity has not been previously recognized. A patient with relapsed multiple myeloma who developed bortezomib-induced severe recurrent hepatitis is described. The importance of recognizing this rare potential toxicity is highlighted in order to discontinue this agent if liver adverse reaction is suspected.<< Would be interesting to read the whole thing. What type of hepatitis? Do we now have to run additional tests for liver function during Velcade treatment? Cheers, Tuck